CJC-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-29 and is reviewed periodically as new material appears.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Political debates after the handover have centred around the region's democratic development and the Chinese central government's adherence to the "one country, two systems" principle. After reversal of the last colonial era Legislative Council democratic reforms following the handover, the regional government unsuccessfully attempted to enact national security legislation pursuant to Article 23 of the Basic Law. The central government decision to implement nominee pre-screening before allowing chief executive elections triggered a series of protests in 2014 which became known as the Umbrella Revolution. Discrepancies in the electoral registry and disqualification of elected legislators after the 2016 Legislative Council elections and enforcement of national law in the West Kowloon high-speed railway station raised further concerns about the region's autonomy. In June 2019, mass protests erupted in response to a proposed extradition amendment bill permitting the extradition of fugitives to mainland China. The protests are the largest in Hong Kong's history, with organisers claiming to have attracted more than three million Hong Kong residents.
For Bukele to run for president with Nuevas Ideas, he was required to register the party with the Supreme Electoral Court (TSE). Although Nuevas Ideas had enough signatures to register, Bukele believed that the TSE would not register the party before the 29 July 2018 presidential nomination deadline. Bukele registered as a member of Democratic Change and sought the party's presidential nomination before the deadline, but the TSE canceled the party's registration four days before the deadline because Democratic Change failed to receive over 50,000 votes during the 2015 legislative elections. On 29 July 2018, Bukele registered with the right-wing Grand Alliance for National Unity (GANA) and received the party's presidential nomination. He selected Félix Ulloa, a lawyer, as his vice-presidential candidate. Bukele used social media such as Facebook, Instagram, and Twitter extensively throughout his campaign to communicate with his supporters. He did not attend either of the two presidential debates, in December 2018 and January 2019, despite saying that he would attend, claiming that the debate rules were not explained to him. Bukele was the election's front-runner, leading virtually every poll by a substantial margin. His three opponents were ARENA's Carlos Calleja, a businessman who owned the Super Selectos supermarket chain; the FMLN's former minister of foreign affairs Hugo Martínez, and Vamos' Josué Alvarado, a businessman. On election day, 3 February 2019, Bukele defeated Calleja, Martínez, and Alvarado with 53.1 percent of the vote.
=== Simmons === Dr. Simmons is a Black Mesa scientist. He is seen in Half-Life: Blue Shift. In Blue Shift, Dr. Simmons is seen fixing a battery in Dr. Rosenberg's office, along with Dr. Walter Bennett. The three scientists soon get it fixed with the help of Barney Calhoun, and they start their teleportation out of Black Mesa. The four successfully make it out of the facility, making Dr. Simmons one of the few known survivors of the incident. They open the gates and start their journey to the outside world with an SUV. Simmons does not talk at all in the game, and his first name is unknown. Furthermore, his final fate is unknown like all of his colleagues.
=== List of well known fractionation effects === A number of common processes fractionate hydrogen isotopes to produce the isotope variations found in nature. Common physical processes include precipitation and evaporation. Chemical reactions can also heavily influence the partitioning of heavy and light isotopes between pools. The rate of a chemical reaction depends in part on the energies of the chemical bonds formed and broken in the reaction. Since different isotopes have different masses, the bond energies differ between isotopologues of a chemical species. This will result in a difference in the rate of a reaction for the different isotopologues, resulting in a fractionation of the different isotopes between the reactant and product in a chemical reaction. This is known as the kinetic isotope effect (KIE). A classic example of KIE is the DHR difference in the equilibrium between H2O and H2 which can have an α value of as much as 3–4.
Sources: en.wikipedia.org
British garrisons in India contributed 18,534 British officers and men, as well as an estimated 10,000 Indian auxiliaries deployed to assist them. India also sent 7,000 horses, ponies and mules. Indian auxiliaries were only employed in non-combatant roles. The Natal Indian Ambulance Corps, created by Gandhi and financed by the local Indian community, served at the battles of Colenso and Spion Kop.
Initial research work was done by Alfred Champagnat at BP's Lavera Refinery in France; a small pilot plant there started operations in March 1963, and the same construction of the second pilot plant, at Grangemouth Oil Refinery in Britain, was authorized. The term SCP was coined in 1966 by Carroll L. Wilson of MIT. The "food from oil" idea became quite popular by the 1970s, with Champagnat being awarded the UNESCO Science Prize in 1976, and paraffin-fed yeast facilities being built in a number of countries. The primary use of the product was as poultry and cattle feed. The Soviets were particularly enthusiastic, opening large "BVK" (belkovo-vitaminny kontsentrat, i.e., "protein-vitamin concentrate") plants next to their oil refineries in Kstovo (1973) and Kirishi (1974). The Soviet Ministry of Microbiological Industry had eight plants of this kind by 1989. However, due to concerns of toxicity of alkanes in SCP and pressured by the environmentalist movements, the government decided to close them down, or convert to some other microbiological processes. Quorn is a range of vegetarian and vegan meat-substitutes made from Fusarium venenatum mycoprotein, sold in Europe and North America. Another type of single cell protein-based meat analogue (which does not use fungi however but rather bacteria) is Calysta. Other producers are Unibio (Denmark) Circe Biotechnologie (Austria) and String Bio (India). SCP has been argued to be a source of alternative or resilient food.
== Research == Due to its high biocompatibility, bioactivity, osteoconductive and/or osteoinductive capacity, nontoxicity, nonimmunogenic properties, and noninflammatory behavior, hydroxyapatite is available and used as a bone filler and as coatings on prostheses. Designing bone scaffolds with a higher capability of promoting bone regeneration is a topical research subject. Composite 3D scaffolds for bone tissue engineering based on nano-hydroxyapatite and poly-ε-caprolactone were designed. The 3D composite scaffolds showed good cytocompatibility and osteogenic potential, which is specifically recommended in applications when faster mineralization is needed, such as osteoporosis treatment.
Sources: en.wikipedia.org
==== LRRK2 gene ==== The LRRK2 gene (PARK8) encodes for the protein leucine-rich repeat kinase 2 (LRRK2/dardarin). Mutations in the LRRK2 gene account for the majority of autosomal-dominant Parkinson's disease cases. These mutations are the most common known cause of familial and sporadic PD, accounting for approximately 5% of individuals with a family history of the disease and 1% of apparently sporadic cases. Many individuals carrying LRRK2 mutations do not develop PD, and estimates of the likelihood of developing PD vary widely with different mutations. LRRK2 is reported to have over 100 genetic coding variants. Of these, only six (G2019S, I2020T, R1441C/G/H, and Y1699C) have been reliably shown to be pathogenic, based on PD family groupings, and three more (I1372V, R1628P, and G2385R) are suspected to be PD genetic risk factors. The occurrence of LRRK2 variants differs based on population and ethnicity. G2019S is found in most countries, with higher frequency in Ashkenazi Jewish and Berber populations. R1628P and G2385R appear in Asian populations. LRRK2 is involved in the protein uptake, movement and clearance activities of the endolysosomal system, which degrades and removes unwanted proteins, preventing toxic build-up. LRRK2 and alpha-synuclein interact. Some LRRK2 mutations have been linked to dysfunctional protein degradation and clearance. For example, G2019S mutations appear to reduce the ability to clear alpha-synuclein, the protein which forms Lewy bodies. G2019S may also be linked to tau pathology.
Mitochondria are self-replicating double membrane-bound organelles that occur in various numbers, shapes, and sizes in the cytoplasm of the cell. Aerobic respiration in the mitochondria generates the cell's energy by oxidative phosphorylation, using oxygen to release energy stored in cellular nutrients (typically pertaining to glucose) to generate adenosine triphosphate (ATP). Mitochondria are descended from bacteria that formed an endosymbiotic relationship with ancient prokaryotes. Mitochondria multiply by binary fission and have their own DNA contained in multiple small circular chromosomes. The mitochondrial DNA (mtDNA) is very small compared to nuclear DNA, but it codes for 13 proteins involved in mitochondrial energy production and specific transfer RNAs (tRNAs). Mitochondria also have their own ribosomes known as mitoribosomes.
== Further reading == Bates, H. E. (1946). The Tinkers of Elstow: the Story of the Royal Ordnance Factory run by J. Lyons and Company Limited for the Ministry of Supply for the World War of 1939–1945. Privately published, Bird, Peter J. (1994). LEO: the First Business Computer. Wokingham: Hasler Publishing Limited. ISBN 0-9521651-0-4. Bird, Peter (2000). The First Food Empire. A History of J. Lyons & Co. Phillmore. Chichester, West Sussex. ISBN 1-86077-132-7. Ferry, Georgina (2003). A Computer Called LEO. Lyons Teashops and the World's First Office Computer. Fourth Estate. London. ISBN 1-84115-185-8. (Published in United States 2004, Hammersmith: Harper Perennial. ISBN 1-84115-186-6.) Caminer, David, John Aris, Peter Hermon and Frank Land (eds). (1996, 1998). User-Driven Innovation (published in the United States as LEO: The incredible Story of the World's first Business Computer). McGraw Hill. ISBN 0-07-009501-9, Harding, Thomas (2019). Legacy : one family, a cup of tea and the company that took on the world. London: William Heinemann. ISBN 978-1785150890.
== History == Food processing dates back to the prehistoric ages when crude processing incorporated fermenting, sun drying, preserving with salt, and various types of cooking (such as roasting, smoking, steaming, and oven baking), Such basic food processing involved chemical enzymatic changes to the basic structure of food in its natural form, as well served to build a barrier against surface microbial activity that caused rapid decay. Salt-preservation was especially common for foods that constituted warrior and sailors' diets until the introduction of canning methods. Evidence for the existence of these methods can be found in the writings of the ancient Greek, Chaldean, Egyptian and Roman civilizations as well as archaeological evidence from Europe, North and South America and Asia. These tried and tested processing techniques remained essentially the same until the advent of the Industrial Revolution. Examples of ready-meals also date back to before the preindustrial revolution, and include dishes such as Cornish pasty and Haggis. Both during ancient times and today in modern society these are considered processed foods.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.